Efortless BioPharma Update’s Post

When a high placebo response could mean a new drug is not effective, or it could be the result of an inappropriate trial population, the cause needs to be investigated. Analyzing trial data using IQVIA’s Subpopulation Optimization and Modeling Solution (SOMS) can eliminate variables and errors, leading to more informed and effective decision making. Visit our website for more information. https://bit.ly/3w2XOkp #clinicaltrials #dataanalysis

Check on our new (great!) tool for fast and efficient analysis of your AS-MS data!

🎡 A centrifuge plays a crucial role in #clinicaltrials enabling the processing of important biological samples and the gathering of accurate data. In a process known as #centrifugation, they can isolate vital substances such as blood components or cellular materials for diagnostic testing within a clinical trial: https://lnkd.in/ebEZ7rJK

Want to learn more about the safety & efficacy of immediate complete revascularisation (ICR) and staged complete revascularisation (SCR) in patients presenting with ACS? 🤳Join Hala K. and Mirvat Alasnag next Tuesday, April 16th, for a Live chat on the substudy of the #BIOVASC randomised trial (to be published in the new issue coming out April 15). 🕰️Tune in at 6:00 PM on you favorite social media channel! #EIJonAir!

Biological samples are a critical part of just about every clinical trial. How do sample requirements and study implications change from phase to phase? Join the discussion in our latest webinar on November 30. Register here: https://lnkd.in/dkGfHQkC

Clinical trials rely on accurate, high-quality assessments to drive drug development success. Discover how blinded independent central reviews (BICRs) for imaging eligibility and disease progression are crucial for achieving this. Download our whitepaper to learn more: https://lnkd.in/enr9ZYNd #ClinicalTrials #BICR #MedicalImaging

What's wrong with the following actual chart titles on recently presented posters about Phase 1/2 data in ALS trials? "Drug X slows disease progression by 32%..." "Drug X stabilizes dyspnea through 24 weeks..." "Drug X improved...measures of speech function..." "Drug Y increases probability of complication-free survival" "Drug Y attenuated disease progression by 29.2%..." "Drug Y slowed decline of physical functions..." ...it's that these are all explicit claims about causation, when the most that can be claimed is correlation. This practice is unscientific and indefensible; at a bare minimum it inflates hope beyond what the data support. PIs and Sponsors need to do better.

🧬 Research shows the PaRTI-Seq gDNA-based assay effectively reduced host background and boosts microbial reads, enhancing sensitivity for accurate diagnosis. #Sepsis #mNGS #Innovation https://lnkd.in/gfznKcDx

Rare Disease Peeps…Fun Facts on how Science works… Read ALL 56 pages of this document before commenting…STUDY it before commenting… “Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry” https://lnkd.in/e5DSRg9q FACTS you NEED TO KNOW! Language in writing is IMPORTANT! #1 Science begins with a theory #2 Science is ALWAYS changing #3 Science changes as innovation progresses #4 Science can be biased and based on OBSERVATIONS, dependent on KNOWLEDGE, REPEATION, a PERSONS BELIEVE, EXPERIENCE and THEIR OWN PERCEPTIONS. Hince, the STAUS QUO is a MOVING TARGET and ALWAYS changes! The status quo needs to change sometimes! We do not grow without change, if we do not take calculated risks, we will NEVER know if it will work. Many do not know how drug effacacy is “graded”. Though we ALL want Safety, however, EFFICACY IS SUBJECTIVE! READ THAT AGAIN! The FDA has guidelines, Yes, only RECOMMENDATIONS of how effective a drug is. Currently, it is graded on “clinical” observation and data. My questions? Where does the PATIENT VOICE fit in? Does it matter? Where does REAL LIFE fit in? #PROMISINGPATHWAYS

TrialKey boasts a market-leading accuracy of over 90% based on precision and recall. Its accuracy consistency across trial phases and strong performance in predicting outcomes for rare or novel conditions make it a game-changer. TrialKey leverages extensive data on general trial practices, instilling confidence in researching rare conditions. Looking ahead, we're gathering data to develop a model for predicting FDA approvals, aiming to overcome current data transparency challenges. TrialKey is poised to revolutionise clinical research by providing reliable predictions and encouraging the exploration of rare conditions. #clinicalresearch #realworldevidence #rareconditions #healthcareinnovation #predictiveanalytics